loading page

Children’s Oncology Group Blueprint for Research: Acute Lymphoblastic Leukemia
  • +5
  • Mignon Loh,
  • Elizabeth Raetz,
  • Deepa Bhojwani,
  • Meenakshi Devidas,
  • Lia Gore,
  • Karen Rabin,
  • Sarah Tasian,
  • David Teachey
Mignon Loh
Seattle Children's Research Institute

Corresponding Author:[email protected]

Author Profile
Elizabeth Raetz
NYU Langone Health Perlmutter Cancer Center
Author Profile
Deepa Bhojwani
University of Southern California Norris Comprehensive Cancer Center
Author Profile
Meenakshi Devidas
St Jude Children's Research Hospital Department of Oncology
Author Profile
Lia Gore
University of Colorado Anschutz Medical Campus Department of Pediatrics
Author Profile
Karen Rabin
Texas Children's Cancer Center and Hematology Centers
Author Profile
Sarah Tasian
University of Pennsylvania
Author Profile
David Teachey
University of Pennsylvania
Author Profile


Cure rates for acute lymphoblastic leukemia (ALL), the most common childhood cancer have steadily improved over the past five decades. This is due to intensifying systemic therapy, recognizing and treating the central nervous system as a sanctuary site, and implementing modern risk stratification to deliver varying intensities of therapy based on age, presenting white blood count (WBC), sentinel somatic genetics, and therapy response. Recently, numerous Children’s Oncology Group trials have demonstrated the lack of benefit of intensifying traditional chemotherapy, providing evidence that new approaches are needed to cure the patients for whom cure has been elusive. Distinguishing those who require intensive or novel therapeutic approaches from others who will be cured with minimal therapy is key for future trials. Incorporating new genomic biomarkers and more sensitive measures of minimal/measurable residual disease (MRD) provide opportunities to achieve these goals.
06 Jul 2023Assigned to Editor
06 Jul 2023Submission Checks Completed
06 Jul 2023Submitted to Pediatric Blood & Cancer
08 Jul 2023Review(s) Completed, Editorial Evaluation Pending
08 Jul 2023Editorial Decision: Accept